# Appendix G

# CCIIO Quality Improvement Strategy (QIS) Implementation Plan, Progress, and Modification Forms

Please submit applicable form(s)

# QIS Implementation Plan

*Submission date (please indicate the date you are submitting this QIS form via HIOS or SERFF)*

*Use this form to provide the baseline details for and to describe your quality improvement strategy (QIS). Please retain a copy of this completed QIS Implementation Plan form so that it is available for future reference when reporting on activities conducted to implement the QIS. CMS will also keep each QIS Implementation Plan form on file as a reference while this particular QIS is in place.*

*For any fields that do not apply, please simply leave them **blank**. There is no need to indicate "NA" or "not applicable" unless specifically instructed to do so for that criterion. For detailed instructions, please refer to the Quality Improvement Strategy: Technical Guidance and User Guide for the current plan year on the Marketplace Quality Initiatives website.*

*If you are an issuer that:*

1. *Is discontinuing a current QIS and implementing a new one, select **New QIS After Discontinuing a QIS Submitted During a Prior Qualified Health Plan (QHP) Application Period** and submit the Implementation Plan form to describe the QIS that will be implemented for the 2025 Plan Year. These issuers should also report on progress to close out the discontinued QIS by submitting a QIS Progress Report form.*
2. *Is participating in QIS for the first time, or implementing an additional QIS, select **New QIS with No Previous QIS submission** and submit only the QIS Implementation Plan form.*

***For CMS Use Only***

## QIS Submission Type

### *Part A. New QIS Submission*

These fields are required but will not be scored as part of the QIS evaluation.

**1. Type of QIS Submission**

Select the option that describes the type of QIS submission and follow the instructions to complete the submission.

| Type of QIS | Instructions |
|---|---|
| ○ **New QIS After Discontinuing a QIS Submitted During a Prior Qualified Health Plan (QHP) Application Period**[1] | Issuers must complete 2 forms:<br>1. Complete the Background Information section (Parts A, B, and C) and the Implementation Plan section (Parts D and E) of the Implementation Plan form to submit the new QIS.<br>2. Complete a Progress Report form to close out the discontinued QIS. See instructions in the QIS Progress Report form: "Progress Report Closeout Form." |
| ○ **New QIS**[2] **with No QIS on file** | Complete the Background Information section (Parts A, B, and C) and the Implementation Plan section (Parts D and E) of the Implementation Plan form to submit the new QIS. |

[1] A new QIS is required if an issuer changes its QIS market-based incentive sub-type, the QIS is not having the expected impact, or the QIS results in negative outcomes or unintended consequences.

[2] A "new QIS" is defined as a QIS that has not been previously submitted to an Exchange.

**2. Targets All QHPs and Product Types Offered Through an Exchange**

2a. Indicate if this QIS is applicable to all eligible QHPs you offer or are applying to offer through the Exchanges, or to a subset of eligible QHPs.

- ◯ All QHPs
- ◯ Subset of QHPs[3]*

**Note*:** *If "Subset of QHPs" was selected above, an additional QIS Implementation Plan(s) must be submitted for eligible QHPs not covered by this QIS.*

2b. Select the relevant product types to which the QIS applies. Check all that apply.

- ☐ Health Maintenance Organization (HMO)
- ☐ Point of Service (POS)
- ☐ Preferred Provider Organization (PPO)
- ☐ Exclusive Provider Organization (EPO)

[3] An issuer that previously covered all eligible QHPs with a single QIS may choose to cover a subset of QHPs with its existing QIS in subsequent years, but must submit an additional QIS form(s) to cover its remaining eligible QHPs. Similarly, an issuer that previously covered subsets of its eligible QHPs with different quality improvement strategies may discontinue one or more of its strategies by submitting a QIS form(s) to close them out. The issuer must also ensure all eligible QHPs are covered by an existing or new QIS.

## Background Information

### *Part B. Issuer Information*

These fields are required but will not be scored as part of the QIS evaluation.

3. **Issuer Legal Name**

4. **Company Legal Name**

5. **HIOS Issuer ID**

6. **Issuer State**

7. **QIS Primary Contact's First Name**

**QIS Primary Contact's Last Name**

8. **QIS Primary Contact's Title**

9. **QIS Primary Contact's Phone** **Ext.**

10. **QIS Primary Contact's Email**

11. **QIS Secondary Contact's First Name**

**QIS Secondary Contact's Last Name**

12. **QIS Secondary Contact's Title**

13. **QIS Secondary Contact's Phone** **Ext.**

14. **QIS Secondary Contact's Email**

15. **Date Issuer Began Offering Coverage Through the Exchange**

***Note:*** *For all date fields in this form, use the down arrow key to activate the calendar and then use the mouse or arrow keys to navigate to the correct date.*

## 16. Current Payment Model(s) Description

Select the category(ies) of payment models that are used by the issuer across its Exchange product line. Provide the percentage of payments in each payment model category[4] used by the issuer across its Exchange product line. The total percentage of payments across all four payment model types should equal approximately 100 percent.[5]

***Note:*** *These percentages can be estimates and do not need to be exact figures. Issuers may update this information year to year, as needed.*

| Payment Model Type | Payment Model Description | Provide Percentage |
|---|---|---|
| ☐ **Fee for Service – No Link to Quality and Value** | Payments are based on volume of services and not linked to quality or efficiency. | ☐ % |
| ☐ **Fee for Service – Linked to Quality and Value** | At least a portion of payments vary based on the quality or efficiency of health care delivery. | ☐ % |
| ☐ **Alternative Payment Models Built on Fee for Service Architecture** | Some payment is linked to the effective management of a segment of the population or an episode of care. Payments are still triggered by delivery of services, but there are opportunities for shared savings or two-sided risk. | ☐ % |
| ☐ **Population-based Payment** | Payment is not directly triggered by service delivery, so payment is not linked to volume. Clinicians and organizations are paid and responsible for the care of a beneficiary for a long period (e.g., more than one year). | ☐ % |
| **Total** | Please confirm the total percentage of payments across all four payment model type categories equals approximately 100%. | 0 % |

[4] Categories of payment models are defined in the *Alternative Payment Model Framework and Progress Tracking (APM FPT) Work Group – Alternative Payment Model (APM) Framework Final White Paper,* available at: https://hcp-lan.org/workproducts/apm-whitepaper.pdf. See the *QIS Technical Guidance and User Guide* for the current plan year, available on the Marketplace Quality Initiatives website, for examples of payment models within each category.

[5] To calculate the percentage of payments for Fee for Service payments linked to quality or value, and/or Alternative Payment Models tied to quality or value, issuers should use the calculation methodologies defined in the *Measuring Progress: Adoption of Alternative Payment Models in Commercial, Medicare Advantage, and State Medicaid Programs (APM Measurement Effort) Final Paper,* available at: http://hcp-lan.org/workproducts/apm-measurement-final.pdf. See Table 1 (p. 7-10) for instructions to calculate the percentage of payments for these two payment model categories.

## *Part C. Data Sources Used for Goal Identification and Monitoring Progress*

This field is required but will not be scored as part of the QIS evaluation.

**17. Data Sources**

Indicate the data sources used for identifying QHP enrollee population needs and supporting the QIS rationale (Element 23). Check all that apply.

| **Data Sources** |
|---|
| ☐ Internal issuer enrollee data |
| ☐ Medical records |
| ☐ Claim files |
| ☐ Surveys (enrollee, beneficiary satisfaction, other) |
| ☐ Plan data (complaints, appeals, customer service, other) |
| ☐ Registries |
| ☐ Census data<br>Specify Type (e.g., block, tract, ZIP Code): |
| ☐ Area Health Resource File (AHRF) |
| ☐ All-payer claims data |
| ☐ State health department population data |
| ☐ Regional collaborative health data |
| ☐ Other: Please describe. Do not include company identifying information in your data source description. *(100 character limit)* |

## QIS Implementation Plan Section

### *Part D. QIS Summary*

These fields are required but will not be scored as part of the QIS evaluation.

**18. QIS Title**

Provide a short title for the QIS.

*(200 character limit)*

**19. QIS Description**

19a. Provide a brief summary description of the QIS. The description must include the market-based incentive type(s) and topic area(s) selected in Elements 21 and 22.

*(1,000 character limit)*

19b. Is the QIS described above part of a mandatory state initiative?

○ Yes ○ No

19c. Is the QIS submission[6] a strategy that the issuer currently has in place for its Exchange product line and/or for other product lines?

○ Yes ○ No

[6] Issuers may use existing strategies employed in non-Exchange product lines (e.g., Medicaid, commercial) if the existing strategies are relevant to their QHP enrollee populations and meet the QIS requirements and criteria.

If “Yes” was checked for either/both of the above, please describe the state initiative and/or current issuer strategy.

*(1,000 character limit)*

## *Part E. QIS Requirements*

**The Elements in Part E will be scored as part of the QIS evaluation**.

**20. QIS Goals**

**Describe the overall goal(s) of the QIS (no more than two).**

***Note:*** *The topic area(s) selected in Element 22 and the measure(s) described in Element 25 should be linked to these goals. Please do not include specific performance targets or timelines to the goals because this Implementation Plan Form will remain on file, and references to specific years or performance targets will become outdated over time.*

**QIS Goal 1:**

*(500 character limit)*

**QIS Goal 2:**

*(500 character limit)*

**21. Market-based Incentive Type(s) (Must Pass)**

Select the sub-type of market-based incentive(s) the QIS includes. Check all that apply. If either "In-kind incentives," "Other provider market-based incentives," or "Other enrollee market-based incentives" is selected, provide a brief description in the space provided.

**Provider Market-based Incentives:**

- ☐ Increased reimbursement
- ☐ Bonus payment
- ☐ In-kind incentives (Provide a description in the space below.)

*(500 character limit)*

- ☐ Other provider market-based incentives (Provide a description in the space below.)

*(500 character limit)*

**Enrollee Market-based Incentives:**

- ☐ Premium credit
- ☐ Co-payment reduction or waiver
- ☐ Co-insurance reduction
- ☐ Cash or cash equivalents
- ☐ Other enrollee market-based incentives (Provide a description in the space below.)

*(500 character limit)*

**22. Topic Area Selection (Must Pass)**

Select the topic area(s) this QIS addresses, as defined in the Patient Protection and Affordable Care Act.[7] Issuers are required to select the "Reduce health and health care disparities" topic area within at least one of their quality improvement strategies on file.[8] Check each topic area that applies.

| QIS Topic Area | Example Activities Cited in the Patient Protection and Affordable Care Act |
|---|---|
| ☐ **Improve health outcomes** | ▪ Quality reporting<br>▪ Effective case management<br>▪ Care coordination<br>▪ Chronic disease management<br>▪ Medication and care compliance initiatives |
| ☐ **Prevent hospital readmissions** | ▪ Comprehensive program for hospital discharge that includes:<br>– Patient-centered education and counseling<br>– Comprehensive discharge planning<br>– Post-discharge reinforcement by an appropriate health care professional |
| ☐ **Improve patient safety and reduce medical errors** | ▪ Appropriate use of best clinical practices<br>▪ Evidence-based medicine<br>▪ Health information technology |
| ☐ **Implement wellness and health promotion activities** | ▪ Smoking cessation<br>▪ Weight management<br>▪ Stress management<br>▪ Healthy lifestyle support<br>▪ Diabetes prevention |
| ☐ **Reduce health and health care disparities** | ▪ Language services<br>▪ Community outreach<br>▪ Cultural competency trainings |

If the "Reduce health and health care disparities" Topic Area is selected, what population(s) does(do) the QIS address?

*(500 character limit)*

[7] Implementation of wellness and health promotion activities are cited in Section 2717(b) of the Patient Protection and Affordable Care Act. All other activities are cited in Section 1311(g)(1) of the Patient Protection and Affordable Care Act.

[8] Beginning with the 2024 Plan Year, issuers are required to address at least two topic areas in their quality improvement strategies on file with "Reduce health and health care disparities" as one of the topic areas, as cited in the Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2023 (87 FR 27208).

**23. Rationale for QIS (Must Pass)**

Provide a rationale for the QIS that describes:

- The issuer's current QHP enrollee population(s) and
- How the QIS will address the needs of the current QHP enrollee population(s).

*(1,500 character limit)*

**24. Activity(ies) That Will Be Conducted to Implement the QIS (Must Pass)**

24a. List the activities that will be implemented to achieve the goals described in Element 20.

*(1,500 character limit)*

24b. Describe how the activities listed in Criterion 24a relate to the market-based incentive(s) selected in Element 21.

*(1,500 character limit)*

24c. Describe how the activities listed in Criterion 24a relate to the topic area(s) selected in Element 22.

*(1,500 character limit)*

**25. Goal(s), Measure(s), and Performance Target(s) to Monitor QIS Progress (Must Pass)**

For Goal 1, identify at least one (but no more than two) primary measure(s) used to track progress toward meeting the goal.

**Measure 1a**

25a. Measure 1a Name:

Provide a narrative description of the measure numerator and denominator or data point calculation method.

*(500 character limit)*

Is this a consensus-based entity (CBE)-endorsed measure?[9] ○ Yes ○ No

If yes, provide the 4-digit ID number:

If yes, did the issuer modify the CBE-endorsed measure specification?

○ Yes ○ No

25b. Describe how Measure 1a supports the tracking of performance related to Goal 1.

*(1,000 character limit)*

[9] The CBE sets measure evaluation criteria through experts and multi-stakeholder groups involved in the evaluation process. For further details regarding CBE endorsed quality measures, please visit the CBE measure database (http://www.p4qm.org/measures).

25c. Baseline Assessment:[10] Provide the baseline results by **either**:

- Calculating the rate and providing the associated numerator and denominator:
(***Note:*** *The numerator and denominator should calculate to the rate provided*)

Calculated Rate: ☐

Numerator: ☐

Denominator: ☐

**- OR -**

- Indicating the data point if the measure is not a rate:

Data Point: ☐

25d. Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline assessment provided in Criterion 25c:

☐ – ☐

25e. Provide the numerical value performance target for this measure *(*i.e., the target rate or data point the QIS intends to achieve):

(***Note:*** *This entry should be a rate (%) or a data point target, NOT a percentage change.*)

☐

**Measure 1b**

25f. Measure 1b Name: ☐

Provide a narrative description of the measure numerator and denominator or data point calculation method.

*(500 character limit)*

☐

Is this a consensus-based entity (CBE)-endorsed measure? ○ Yes ○ No

If yes, provide the 4-digit ID number: ☐

If yes, did the issuer modify the CBE-endorsed measure specification?

○ Yes ○ No

[10] Baseline assessment results should report performance before implementation of the QIS.

25g. Describe how Measure 1b supports the tracking of performance related to Goal 1.

*(1,000 character limit)*

25h. Baseline Assessment: Provide the baseline results by **either**:

- Calculating the rate and providing the associated numerator and denominator:
(***Note:*** *The numerator and denominator should calculate to the rate provided*)

Calculated Rate:

Numerator:

Denominator:

**- OR -**

- Indicating the data point if the measure is not a rate:

Data Point:

25i. Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the covered by the baseline assessment provided in Criterion 25h:

– 

25j. Provide the numerical value performance target for this measure (i.e., the target rate or data point the QIS intends to achieve):

(***Note:*** *This entry should be a rate (%) or a data point target, NOT a percentage change.*)

**QIS Goal 2:**

For Goal 2, identify at least one (but no more than two) primary measure(s) used to track progress toward meeting the goal.

25k. **Measure 2a**

Measure 2a Name:

Provide a narrative description of the measure numerator and denominator or data point calculation method.

*(500 character limit)*

Is this a consensus-based entity (CBE)-endorsed measure? ○ Yes ○ No

If yes, provide the 4-digit ID number:

If yes, did the issuer modify the CBE-endorsed measure specification?

○ Yes ○ No

25l. Describe how Measure 2a supports the tracking of performance related to Goal 2.

*(1,000 character limit)*

25m. Baseline Assessment: Provide the baseline results by **either**:

- Calculating the rate and providing the associated numerator and denominator (***Note:*** *The numerator and denominator should calculate to the rate provided*):

Calculated Rate:

Numerator:

Denominator:

**- OR -**

- Indicating the data point if the measure is not a rate:

Data Point:

25n. Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline assessment provided in Criterion 25m:

[ ] – [ ]

25o. Provide the numerical value performance target for this measure (i.e., the target rate or data point the QIS intends to achieve):

(***Note:*** *This entry should be a rate (%) or a data point target, NOT a percentage change.*)

[ ]

25p. **Measure 2b**

Measure 2b Name: [ ]

Provide a narrative description of the measure numerator and denominator or data point calculation method.

*(500 character limit)*

[ ]

Is this a consensus-based entity (CBE)-endorsed measure? ○ Yes ○ No

If yes, provide the 4-digit ID number: [ ]

If yes, did the issuer modify the CBE-endorsed measure specification?

○ Yes ○ No

25q. Describe how Measure 2b supports the tracking of performance related to Goal 2.

*(1,000 character limit)*

[ ]

25r. Baseline Assessment: Provide the baseline results by **either**:

- Calculating the rate and providing the associated numerator and denominator: (***Note:*** *The numerator and denominator should calculate to the rate provided.*)

  Calculated Rate: ☐

  Numerator: ☐

  Denominator: ☐

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point: ☐

25s. Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline assessment provided in Criterion 25r:

☐ – ☐

25t. Provide the numerical value performance target for this measure (i.e., the target rate or data point the QIS intends to achieve):

(***Note:*** *This entry should be a rate (%) or a data point target, NOT a percentage change.*)

☐

**26. Timeline for Implementing the QIS**

26a. QIS Initiation/Start Date:

26b. Describe the milestone(s) and provide the date(s) for each milestone (i.e., when activities described in Element 24 will be implemented). At least one milestone is required.

*(100 character limit per milestone)*

| | **Milestone(s)** | **Date for Milestone(s)** |
|---|---|---|
| 1. | | |
| 2. | | |
| 3. | | |
| 4. | | |
| 5. | | |
| 6. | | |
| 7. | | |
| 8. | | |
| 9. | | |
| 10. | | |

**27. Risk Assessment (Must Pass)**

27a. List all known or anticipated barriers to implementing QIS activities.

*(750 character limit)*

If no barriers were identified, describe how you assessed risk in the box below. If barriers were identified above, this box should be left blank.

*(750 character limit)*

27b. Describe the mitigation activities that will be incorporated to address **each** barrier identified in Criterion 27a. If there were no barriers identified, this box should be left blank.

*(1,500 character limit)*

Optional: *If there is any additional information you would like to provide regarding your QIS Implementation Plan, please do so in the box below.*

*(1,500 character limit)*

# QIS Progress Report Form

*Submission date (please indicate the date you are submitting this QIS form via HIOS or SERFF)* ☐

*Use this form to report on progress made during the previous year of your quality improvement strategy (QIS). Please refer to your baseline QIS Implementation Plan and any subsequent modifications for baseline data.*

☐ *Confirm you have reviewed your baseline QIS Implementation Plan (and associated Modification Summary Supplement, if applicable) in preparing this submission.*

*For detailed instructions, please refer to the Quality Improvement Strategy: Technical Guidance and User Guide for the current plan year on the* Marketplace Quality Initiatives website.

***PLEASE NOTE: Both issuers who are CONTINUING or DISCONTINUING a QIS need to submit a Progress Report form.*** *There are two scenarios for issuers:*

1. ***Progress Report:*** *Issuers who are continuing their current QIS (with or without modifications) should select* ***Progress Report*** *to report on progress made during the previous year of your QIS.*
2. ***Progress Report Closeout Form:*** *Issuers discontinuing their current QIS and implementing a new one should select* ***Progress Report Closeout Form*** *and submit the Progress Report form to close out the discontinued QIS. These issuers should also describe the QIS that will be in place for the 2025 Plan Year by submitting a QIS Implementation Plan for the new QIS.*

***For CMS Use Only*** ☐

## QIS Submission Type

### *Part A. Progress Report or Closeout QIS Submission*

These fields are required but will not be scored as part of the QIS evaluation.

**1. Type of QIS Submission**

Select the option that describes the type of QIS submission and follow the instructions to complete the submission.

| Type of QIS | Instructions |
|---|---|
| ◯ **Progress Report** | Issuers must complete one[1] form:<br>1. Complete the Background Information section (Parts A and B), and the Progress Report Summary section (Part C) of the Progress Report form to report progress on your baseline QIS. |
| ◯ **Progress Report Closeout Form** | Issuers must complete 2 forms:<br>1. Complete the Background Information section (Parts A and B) and the Progress Report Summary section (Part C) of the Progress Report form to close out the discontinued QIS, reporting on progress up until the strategy was discontinued.<br>2. Complete a new Implementation Plan form. See instructions in the QIS Implementation Plan form: New QIS after Discontinuing a QIS Submitted During a Prior QHP Application Period. |

**QIS Title**

Restate the short title for the QIS being reported on. *(200-character limit)*

[1] If continuing with modifications, issuers must also complete a Modification Summary Supplement form. See instructions in the QIS Modification Summary Supplement form: Continuing a QIS with Modifications.

## Background Information

### *Part B. Issuer Information*

These fields are required but will not be scored as part of the QIS evaluation. Issuers may update the information in Part B from year to year, as needed.

**2. Issuer Legal Name**

**3. Company Legal Name**

**4. HIOS Issuer ID**

**5. Issuer State**

**6. QIS Primary Contact's First Name**

**QIS Primary Contact's Last Name**

**7. QIS Primary Contact's Title**

**8. QIS Primary Contact's Phone** **Ext.**

**9. QIS Primary Contact's Email**

**10. QIS Secondary Contact's First Name**

**QIS Secondary Contact's Last Name**

**11. QIS Secondary Contact's Title**

**12. QIS Secondary Contact's Phone** **Ext.**

**13. QIS Secondary Contact's Email**

**14. Date Issuer Began Offering Coverage Through the Exchange**

**Note:** *For all date fields in this form, use the down arrow key to activate the calendar and then use the mouse or arrow keys to navigate to the correct date.*

## 15. Current Payment Model(s) Description

Select the category(ies) of payment models that are used by the issuer across its Exchange product line. Provide the percentage of payments in each payment model category[2] used by the issuer across its Exchange product line. The total percentage of payments across all four payment model types should equal approximately 100 percent.[3]

**Note:** *These percentages can be estimates and do not need to be exact figures. Issuers may update this information year to year, as needed.*

| Payment Model Type | Payment Model Description | Provide Percentage |
|---|---|---|
| ☐ **Fee for Service – No Link to Quality and Value** | Payments are based on volume of services and not linked to quality or efficiency. | ____ % |
| ☐ **Fee for Service – Linked to Quality and Value** | At least a portion of payments vary based on the quality or efficiency of health care delivery. | ____ % |
| ☐ **Alternative Payment Models Built on Fee for Service Architecture** | Some payment is linked to the effective management of a segment of the population or an episode of care. Payments are still triggered by delivery of services, but there are opportunities for shared savings or two-sided risk. | ____ % |
| ☐ **Population-based Payment** | Payment is not directly triggered by service delivery, so payment is not linked to volume. Clinicians and organizations are paid and responsible for the care of a beneficiary for a long period (e.g., more than one year). | ____ % |
| **Total** | Please confirm the total percentage of payments across all four payment model type categories equals approximately 100%. | 0 % |

[2] Categories of payment models are defined in the *Alternative Payment Model Framework and Progress Tracking (APM FPT) Work Group – Alternative Payment Model (APM) Framework Final White Paper,* available at: https://hcp-lan.org/workproducts/apm-whitepaper.pdf. See the QIS Technical Guidance and User Guide for the current plan year, available on the Marketplace Quality Initiatives website, for examples of payment models within each category.
[3] To calculate the percentage of payments for Fee for Service payments linked to quality or value, and/or Alternative Payment Models tied to quality or value, issuers should use the calculation methodologies defined in the *Measuring Progress: Adoption of Alternative Payment Models in Commercial, Medicare Advantage, and State Medicaid Programs (APM Measurement Effort) Final Paper,* available at: https://hcp-lan.org/groups/apm-fpt/apm-report/. See Table 1 (p. 7-10) for instructions to calculate the percentage of payments for these two payment model categories.

## QIS Progress Report Section

### *Part C. QIS Progress Report Summary*

**The Elements in Part C will be scored as part of the QIS evaluation.**

***Note:*** *The Goal(s) and Measure(s) identified in this section (Part C: Progress Report Summary) are the Goal(s) and Measure(s) from the Implementation Plan form (and associated Modification Summary Supplement, if applicable) on file against which QIS progress is measured.*

***Note:*** *All references to Implementation Plan form elements and criteria in this form refer to the Implementation Plan form (and associated Modification Summary Supplement, if applicable) on file.*

***Note: Please make sure to correctly restate the values and information from the most recent Implementation Plan on file and/or the Modification Summary Supplement on file, when applicable.***

**16. Analyze Progress Using Baseline Data, as Documented in the Implementation Plan (Must Pass)**

Restate Goal 1 identified in the Implementation Plan or the Modification Summary Supplement on file, if applicable.

**QIS Goal 1:**

*(500 character limit)*

**Measure 1a:**

16a. Restate Measure 1a name from the Implementation Plan or the Modification Summary Supplement on file, if applicable:

If this a consensus-based entity (CBE)-endorsed measure,[4] please provide the 4-digit CBE-ID number:

[4] The CBE sets measure evaluation criteria through experts and multi-stakeholder groups involved in the evaluation process. For further details regarding CBE endorsed quality measures, please visit the CBE measure database (http://www.p4qm.org/measures).

16b. Baseline Assessment: Restate the baseline results from the Implementation Plan or the Modification Summary Supplement on file, if applicable, by **either**:

- Calculating the rate and providing the associated numerator and denominator: *(**Note:** The numerator and denominator should calculate to the rate provided.)*

  Calculated Rate: ☐

  Numerator: ☐

  Denominator: ☐

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point: ☐

16c. Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline assessment provided in the Implementation Plan or the Modification Summary Supplement on file, if applicable:

☐ – ☐

16d. Provide the Progress Report results by either:

- Calculating the rate and providing the associated numerator and denominator: (**Note:** *The numerator and denominator should calculate to the rate provided.)*

  Calculated Rate: ☐

  Numerator: ☐

  Denominator: ☐

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point: ☐

16e. Provide the Progress Report performance period (i.e., month and year when data collection began and ended) covered by the progress report assessment:

☐ – ☐

16f. Restate the numerical value performance target for this measure *(i.e., the target rate or data point the QIS intends to achieve*) from the Implementation Plan or the Modification Summary Supplement on file, if applicable: (**Note:** *This entry should be a rate (%) or a data point target, NOT a percentage change.)*

☐

16g. Was the performance target achieved?

○ Yes ○ No

**Measure 1b:**

16h. Restate Measure 1b name from the Implementation Plan or the Modification Summary Supplement on file, if applicable:

If this a consensus-based entity (CBE)-endorsed measure, please provide the 4-digit CBE-ID number:

16i. Baseline Assessment: Restate the baseline results from the Implementation Plan or the Modification Summary Supplement on file, if applicable, by **either**:

- Calculating the rate and providing the associated numerator and denominator: (***Note:*** *The numerator and denominator should calculate to the rate provided.*)

  Calculated Rate:

  Numerator:

  Denominator:

**- OR -**

- Indicating the data point, if the measure is not a rate:

  Data Point:

16j. Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline assessment provided in of the Implementation Plan or the Modification Summary Supplement on file, if applicable:

– 

16k. Provide the Progress Report results by **either:**

- Calculating the rate and providing the associated numerator and denominator: (***Note:*** *The numerator and denominator should calculate to the rate provided.*)

  Calculated Rate:

  Numerator:

  Denominator:

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point: [ ]

16l. Provide the Progress Report performance period (i.e., month and year when data collection began and ended) covered by the progress report assessment:

[ ] – [ ]

16m. Restate the numerical value performance target for this measure *(i.e., the target rate or data point the QIS intends to achieve*) from the Implementation Plan or the Modification Summary Supplement on file, if applicable: (***Note:*** *This entry should be a rate (%) or a data point target, NOT a percentage change.*)

[ ]

16n. Was the performance target achieved?

○ Yes ○ No

**QIS Goal 2**

Restate Goal 2 identified in the Implementation Plan or the Modification Summary Supplement on file, if applicable.

**QIS Goal 2:**

*(500 character limit)*

[ ]

**Measure 2a:**

16o. Restate Measure 2a name from the Implementation Plan or the Modification Summary Supplement on file, if applicable:

[ ]

If this a consensus-based entity (CBE)-endorsed measure, please provide the 4-digit CBE-ID number:

[ ]

16p. Baseline Assessment: Restate the baseline results from the Implementation Plan or the Modification Summary Supplement on file, if applicable, by **either**:

- Calculating the rate and providing the associated numerator and denominator: (***Note:*** *The numerator and denominator should calculate to the rate provided.*)

  Calculated Rate: ☐

  Numerator: ☐

  Denominator: ☐

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point: ☐

16q. Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline assessment provided in the Implementation Plan or the Modification Summary Supplement on file, if applicable:

☐ – ☐

16r. Provide the Progress Report results by **either:**

- Calculating the rate and providing the associated numerator and denominator: (***Note:*** *The numerator and denominator should calculate to the rate provided.*)

  Calculated Rate: ☐

  Numerator: ☐

  Denominator: ☐

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point: ☐

16s. Provide the Progress Report performance period (i.e., month and year when data collection began and ended) covered by the progress report assessment:

☐ – ☐

16t. Restate the numerical value performance target for this measure *(i.e., the target rate or data point the QIS intends to achieve*) from the Implementation Plan or the Modification Summary Supplement on file, if applicable: (**Note:** *This entry should be a rate (%) or a data point target, NOT a percentage change*.)

☐

16u. Was the performance target achieved?

○ Yes ○ No

**Measure 2b:**

16v. Restate Measure 2b name from the Implementation Plan or the Modification Summary Supplement on file, if applicable:

If this a consensus-based entity (CBE)-endorsed measure, please provide the 4-digit CBE-ID number:

16w. Baseline Assessment: Restate the baseline results from the Implementation Plan or the Modification Summary Supplement on file, if applicable, by **either**:

- Calculating the rate and providing the associated numerator and denominator: (***Note:*** *The numerator and denominator should calculate to the rate provided.*)

  Calculated Rate:

  Numerator:

  Denominator:

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point:

16x. Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline assessment provided in the Implementation Plan or the Modification Summary Supplement on file, if applicable:

– 

16y. Provide the Progress Report results by **either:**

- Calculating the rate and providing the associated numerator and denominator: (***Note:*** *The numerator and denominator should calculate to the rate provided.)*

  Calculated Rate:

  Numerator:

  Denominator:

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point:

16z. Provide the Progress Report performance period (i.e., month and year when data collection began and ended) covered by the progress report assessment:

[ ] – [ ]

16aa. Restate the numerical value performance target for this measure *(i.e., the target rate or data point the QIS intends to achieve*) from the Implementation Plan or the Modification Summary Supplement on file, if applicable: (**Note:** *This entry should be a rate (%) or a data point target, NOT a percentage change.*)

[ ]

16bb. Was the performance target achieved?

◯ Yes ◯ No

**17. Summary of Progress (Must Pass)**

17a. Please provide a summary of progress covering the following details: (**Note:** *Regardless of if you made progress toward the performance target(s), you will be required to describe any barriers encountered in Criterion 18a and any problems meeting timelines in Criterion 18b*.)

- Indicate why progress was or was not made toward the performance target(s) documented in your QIS Implementation Plan or the Modification Summary Supplement on file, if applicable, and
- Include a description of activities that led to the outcome.

*(1,000 character limit)*

17b. If the issuer selected **"Progress Report Closeout Form"** in Element 1 of *this* Progress Report form, provide the rationale for discontinuing the QIS.

*(1,000 character limit)*

17c. If the issuer received an **"Interim Meets"** determination during the previous QIS Evaluation Period and was instructed to address the deficiencies in its subsequent Plan Year submission, please indicate which elements and/or criteria were updated based on the QIS Evaluation Period Correction Report and describe the changes.

*(1,000 character limit)*

**18. Barriers and Mitigation Activities**

18a. Were barriers encountered in implementing the QIS over time? (**Note:** *If your description of activities in Criterion 17a includes barriers to implementing the QIS, you are still required to complete Criterion 18a and elaborate on those barriers and any other barriers in implementing the QIS, if applicable, by providing the below information.*)

○ Yes ○ No

If "Yes," describe:

- The barriers, and
- The mitigation activities implemented to address **each** barrier.

*(1,500-character limit)*

18b. Were there problems meeting timelines as indicated in the QIS Implementation Plan on file? (**Note:** *If your description of activities in Criterion 17a includes problems meeting timelines, you are still required to complete Criterion 18b and elaborate on those problems and any other problems in meeting timelines, if applicable, by providing the below information.*)

◯ Yes ◯ No

If "Yes," describe:

- The problems in meeting timelines and
- The mitigation activities implemented to address **each** problem in meeting the timeline.

*(1,500-character limit)*

Optional: *If there is any additional information you would like to provide regarding your QIS Progress Report, please do so in the box below.*

*(1,500 character limit)*

# QIS Modification Summary Supplement

*Submission date (please indicate the date you are submitting this QIS form via HIOS or SERFF)*

*Use this form to indicate any modifications to an existing quality improvement strategy (QIS) Implementation Plan on file for the upcoming plan year (making changes to topic areas, goals, activities, measures, performance targets, and/or the product types).* ***Issuers who have previously submitted two (2) Modification Summary Supplement forms for a QIS on file, must submit a QIS Implementation Plan form to replace that QIS.*** *You must also report progress on your current QIS using the separate* ***QIS Progress Report form.***

*For detailed instructions, please refer to the Quality Improvement Strategy: Technical Guidance and User Guide for the current plan year on the* Marketplace Quality Initiatives website.

## QIS Submission Type

### *Part A. QIS Submission*

This field is required but will not be scored as part of the QIS evaluation.

**1. Type of QIS Submission**

Select the option that describes the type of QIS submission and follow the instructions to complete the submission.

| Type of QIS | Instructions |
|---|---|
| ○ **Continuing QIS with Modifications** | Issuers must complete 2 forms:<br>1. Complete the Background Information section (Parts A and B) and the QIS Modification Summary (Part C) of the Modification Summary Supplement to reflect modifications for the upcoming year.<br>2. Complete the QIS Progress Report form to report on progress achieved on your QIS over the past plan year. See instructions in the QIS Progress Report form: Report on Progress. |

**QIS Title**

Restate the short title for the QIS being modified. (200 character limit)

***For CMS Use Only***

## Background Information

### *Part B. Issuer Information*

These fields are required but will not be scored as part of the QIS evaluation. Issuers may update the information in Part B from year to year, as needed.

**2. Issuer Legal Name**

**3. HIOS Issuer ID**

**4. Issuer State**

**5. QIS Primary Contact's First Name**

**QIS Primary Contact's Last Name**

**6. QIS Primary Contact's Email**

**7. QIS Primary Contact's Phone** **Ext.**

## *Part C. QIS Modification Summary*

Complete the following section regarding modifications to the QIS for the upcoming plan year.

**8. Modifying Product Types, Topic Areas, Goals, Activities, and Measures or Associated Performance Targets (Must Pass)**

8a. Which component(s) of your QIS are you modifying for the upcoming plan year? Changes in one component may necessitate modifications to other components. (Check boxes for product types, goals, activities, measures, and performance targets.)

- ☐ Product Types (complete 8b)
- ☐ Topic Areas (complete 8c)
- ☐ Goals (complete 8d)
- ☐ Activities (complete 8e)
- ☐ Measures (complete 8f)
- ☐ Performance Targets (complete 8f)

***Note:*** *ONLY enter information in the fields below for the components you have indicated above.*

Please provide a high-level description of the modifications described below.

*(500 character limit)*

| |
|---|
| |

8b. **Modifying QIS Product Types:** For Product Type changes, indicate whether you are adding and/or removing any Product Types to the QIS originally listed in your Implementation Plan or Modification Summary Supplement on file. Select all that apply.

| | | |
|---|---|---|
| Health Maintenance Organization (HMO) | ☐ Add | ☐ Remove |
| Point of Service (POS) | ☐ Add | ☐ Remove |
| Preferred Provider Organization (PPO) | ☐ Add | ☐ Remove |
| Exclusive Provider Organization (EPO) | ☐ Add | ☐ Remove |

8c. **Modifying QIS Topic Areas**: For Topic Area changes, indicate whether you are adding and/or removing any Topic Areas to the Implementation Plan or Modification Summary Supplement on file. Select all that apply.[1]

Note that if you are modifying the QIS Topic Areas for your existing QIS, you must also use this form to modify the QIS Goals and Activities listed in the Implementation Plan or Modification Summary Supplement on file, if applicable, by completing Criteria 8d and 8e. You may also need to update the QIS Measures and Performance Targets listed in the Implementation Plan or Modification Summary Supplement on file, if applicable, by completing Criterion 8f.

| | | |
|---|---|---|
| Improve health outcomes | ☐ Add | ☐ Remove |
| Prevent hospital readmissions | ☐ Add | ☐ Remove |
| Improve patient safety and reduce medical errors | ☐ Add | ☐ Remove |
| Implement wellness and health promotion activities | ☐ Add | ☐ Remove |
| Reduce health and health care disparities | ☐ Add | ☐ Remove |

If you have added a topic area(s), please describe how that topic area(s) will be addressed within your existing QIS. If you removed a topic area, please describe the rationale or reason for removing.

*(500 character limit)*

*If the "Reduce health and health care disparities" Topic Area is selected, what population(s) does(do) the QIS address?*

*(500 character limit)*

[1] Issuers with a current QIS on file should review the information they included in criterion 24d of their QIS Implementation Plan.

8d. **Modifying QIS Goals:** For modified Goal(s), indicate which Goal(s) you are modifying and state the new Goal(s) in the space provided below. Please do not include specific performance targets or goals tied to a specific calendar year or plan year because this Modification Summary Supplement will remain on file, and references to specific years or performance targets will become outdated over time:

☐ Goal 1

☐ Goal 2

Provide a rationale for the modification(s).

(*500 character limit)*

8e. **Modifying QIS Activities:** If you are modifying Activities, describe them here.

(*500 character limit)*

Provide a rationale for the modification(s).

(*500 character limit)*

8f. **Modifying QIS Measures or Associated Performance Targets:** For modified or new Measures or Associated Performance Targets, select the checkbox for the measure and provide all information. ***Note:*** *Please refer to your QIS on file to verify measure number and to replicate unchanged information*. If you are removing a measure, you just need to state which measure you are removing in the space below (Description of modification) and you do NOT need to fill out any further information for the measure.

Description of modification (e.g., remove measure, change measure or measure specifications, change target, add new measure).

*(500 character limit)*

| |
|---|
| |

☐ **Measure 1a name:** _____

Please select and provide all information for each measure criterion.

Is this a consensus-based entity (CBE)-endorsed measure?[2] ○ Yes ○ No

If yes, provide the 4-digit ID number: _____

Baseline Assessment: Provide the baseline results by either:

- Calculating the rate and providing the associated numerator and denominator: (***Note:*** *The numerator and denominator should calculate to the rate provided.*)

  Calculated Rate: _____

  Numerator: _____

  Denominator: _____

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point: _____

Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline data assessment:

_____ – _____

[2] The CBE sets measure evaluation criteria through experts and multi-stakeholder groups involved in the evaluation process. For further details regarding CBE endorsed quality measures, please visit the CBE measure database (http://www.p4qm.org/measures).

Provide the numerical value performance target for this measure (i.e., the target rate or data point the QIS intends to achieve):

(**Note:** This entry should be a rate (%) or a data point target, NOT a percentage change.)

Provide a rationale for the modifications.

(*500 character limit)*

☐ **Measure 1b name:**

Please select and provide all information for each measure criterion.

Is this a consensus-based entity (CBE)-endorsed measure? ◯ Yes ◯ No

If yes, provide the 4-digit ID number:

Baseline Assessment: Provide the baseline results by **either**:

- Calculating the rate and providing the associated numerator and denominator: (***Note:*** *The numerator and denominator should calculate to the rate provided.*)

  Calculated Rate:

  Numerator:

  Denominator:

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point:

Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline data assessment:

– 

Provide the numerical value performance target for this measure (i.e., the target rate or data point the QIS intends to achieve):

(**Note:** This entry should be a rate (%) or a data point target, NOT a percentage change.)

Provide a rationale for the modifications.

(*500 character limit)*

☐ **Measure 2a name:**

Please select and provide all information for each measure criterion.

Is this a consensus-based entity (CBE)-endorsed measure? ○ Yes ○ No

If yes, provide the 4-digit ID number:

Baseline Assessment: Provide the baseline results by **either**:

- Calculating the rate and providing the associated numerator and denominator:
  (***Note:*** *The numerator and denominator should calculate to the rate provided.*)

  Calculated Rate:

  Numerator:

  Denominator:

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point:

Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline data assessment:

– 

Provide the numerical value performance target for this measure:

(**Note:** This entry should be a rate (%) or a data point target, NOT a percentage change.)

Provide a rationale for the modifications.

(*500 character limit)*

☐ **Measure 2b name:**

Please select and provide all information for each measure criterion.

Is this a consensus-based entity (CBE)-endorsed measure? ○ Yes ○ No

If yes, provide the 4-digit ID number:

Baseline Assessment: Provide the baseline results by **either**:

- Calculating the rate and providing the associated numerator and denominator:
  (***Note:*** *The numerator and denominator should calculate to the rate provided.*)

  Calculated Rate:

  Numerator:

  Denominator:

**- OR -**

- Indicating the data point if the measure is not a rate:

  Data Point:

Provide the baseline performance period (i.e., month and year when data collection began and ended) covered by the baseline data assessment:

– 

Provide the numerical value performance target for this measure (i.e., the target rate or data point the QIS intends to achieve):

(**Note:** This entry should be a rate (%) or a data point target, NOT a percentage change.)

Provide a rationale for the modifications.

(*500 character limit)*